JPS6011013B2 - 動物用薬剤 - Google Patents

動物用薬剤

Info

Publication number
JPS6011013B2
JPS6011013B2 JP47121265A JP12126572A JPS6011013B2 JP S6011013 B2 JPS6011013 B2 JP S6011013B2 JP 47121265 A JP47121265 A JP 47121265A JP 12126572 A JP12126572 A JP 12126572A JP S6011013 B2 JPS6011013 B2 JP S6011013B2
Authority
JP
Japan
Prior art keywords
virus
pharmaceutical
interferon
animals
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP47121265A
Other languages
English (en)
Japanese (ja)
Other versions
JPS4862912A (de
Inventor
クリスチヤン シユトラウプ オツト−
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JPS4862912A publication Critical patent/JPS4862912A/ja
Publication of JPS6011013B2 publication Critical patent/JPS6011013B2/ja
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16732Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761Methods of inactivation or attenuation
    • C12N2710/16764Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP47121265A 1971-12-10 1972-12-05 動物用薬剤 Expired JPS6011013B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2161344A DE2161344C3 (de) 1971-12-10 1971-12-10 Herstellung von Virusstämmen, welche die natürlichen Abwehrmechanismen eines Wirtsorganismus stimulieren, ohne dabei gleichzeitig antigen zu wirken und Arzneimittel zur Prophylaxe und Behandlung von viralen und bakteriellen Infektionen des Menschen und der Tiere, einen solchen Virusstamm enthaltend
DE2161344.5 1971-12-10

Publications (2)

Publication Number Publication Date
JPS4862912A JPS4862912A (de) 1973-09-01
JPS6011013B2 true JPS6011013B2 (ja) 1985-03-22

Family

ID=5827622

Family Applications (2)

Application Number Title Priority Date Filing Date
JP47121265A Expired JPS6011013B2 (ja) 1971-12-10 1972-12-05 動物用薬剤
JP47121264A Expired JPS5924137B2 (ja) 1971-12-10 1972-12-05 弱毒ウイルスの製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP47121264A Expired JPS5924137B2 (ja) 1971-12-10 1972-12-05 弱毒ウイルスの製造方法

Country Status (21)

Country Link
JP (2) JPS6011013B2 (de)
AR (1) AR204075A1 (de)
AT (1) AT326817B (de)
AU (1) AU473209B2 (de)
BE (1) BE792484A (de)
BG (1) BG21417A3 (de)
CA (1) CA988848A (de)
CH (1) CH577558A5 (de)
CS (1) CS189587B2 (de)
DD (1) DD108115A5 (de)
DE (1) DE2161344C3 (de)
DK (1) DK143201C (de)
ES (1) ES409464A1 (de)
FR (1) FR2162637B1 (de)
GB (1) GB1356076A (de)
HU (1) HU167086B (de)
IE (1) IE36995B1 (de)
NL (1) NL178014C (de)
PH (1) PH12597A (de)
SE (1) SE8400283L (de)
ZA (1) ZA728709B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0063657A1 (de) * 1981-04-29 1982-11-03 Merck & Co. Inc. Topische Anwendung von Interferon-Induktoren

Also Published As

Publication number Publication date
ATA1041972A (de) 1975-03-15
DE2161344B2 (de) 1980-05-08
DE2161344C3 (de) 1986-10-02
CS189587B2 (en) 1979-04-30
AT326817B (de) 1975-12-29
NL178014B (nl) 1985-08-01
SE8400283D0 (sv) 1984-01-20
AR204075A1 (es) 1975-11-20
BG21417A3 (de) 1976-05-20
NL7216628A (de) 1973-06-13
GB1356076A (en) 1974-06-12
ZA728709B (en) 1973-08-29
HU167086B (de) 1975-08-28
SU439956A3 (ru) 1974-08-15
SE8400283L (sv) 1984-01-20
JPS5924137B2 (ja) 1984-06-07
FR2162637B1 (de) 1976-07-02
DK143201C (da) 1981-12-14
JPS4862912A (de) 1973-09-01
DK143201B (da) 1981-07-20
FR2162637A1 (de) 1973-07-20
AU4992072A (en) 1974-06-13
DE2161344A1 (de) 1973-06-20
IE36995L (en) 1973-06-10
AU473209B2 (en) 1976-06-17
IE36995B1 (en) 1977-04-13
PH12597A (en) 1979-06-27
CA988848A (en) 1976-05-11
JPS4862919A (de) 1973-09-01
BE792484A (fr) 1973-06-08
ES409464A1 (es) 1976-03-16
NL178014C (nl) 1986-01-02
DD108115A5 (de) 1974-09-05
CH577558A5 (de) 1976-07-15

Similar Documents

Publication Publication Date Title
JPH02243633A (ja) ワクチン製剤
Zygraich et al. In vivo and in vitro properties of a temperature sensitive mutant of infectious bovine rhinotracheitis virus
US4110433A (en) Equine rhinopneumonitis virus
Iosef et al. Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes
CN108969492B (zh) 一种猪瘟口服弱毒冻干疫苗及其制备方法
Glasgow et al. Isoprinosine: lack of antiviral activity in experimental model infections
US4049794A (en) Treatment of infections in animals
US4039656A (en) Production of attenuated viruses
Shipkowitz et al. Antiviral activity of a bis-benzimidazole against experimental rhinovirus infections in chimpanzees
Longley et al. Effect of isoprinosine against challenge with A (H3N2)/Hong Kong influenza virus in volunteers
US6726913B1 (en) Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes
Woodward Rickettsial vaccines with emphasis on epidemic typhus-initial report of an old vaccine trial
JPS6011013B2 (ja) 動物用薬剤
US4017359A (en) Production of non-antigenic attenuated viruses
JP2004508424A (ja) 免疫調節調剤物
CN108703952B (zh) 一种猪瘟口服弱毒冻干疫苗用冻干保护剂及应用
Steffenhagen et al. Evaluation of 6-Azauridine and S-Iododeoxyuridine in the Treatment of Experimental Viral Infections
RU2791454C1 (ru) Способ лечения вирусной диареи молодняка крупного рогатого скота
RU2775580C1 (ru) Способ профилактики инфекционного ринотрахеита у телят
RU2292220C1 (ru) Способ профилактики инфекционного ринотрахеита и парагриппа-3 крупного рогатого скота
Villegas et al. Effect of route of Newcastle disease vaccination on the incidence of airsacculitis in chickens infected with Mycoplasma synoviae
Tan et al. Further studies on feline respiratory virus diseases: 1. Vaccination experiments
JPS6222727A (ja) 感染性気管支炎ワクチン
CN108704131B (zh) 一种猪瘟口服弱毒冻干疫苗用疫苗稀释液及其应用
Gillespie et al. The Prophylactic Effects of E. coli‐Derived Bovine Interferon AlphaI1 on Bovine Virus Diarrhoea Virus Disease in Calves after Intramuscular Administration